APOA1 and cardiovascular disorder: Currently, a disappointing result of negative clinical finding of RVX-208 has been reported, which is acting as an ApoA1 modulator in phase I/II clinical trials for the treatment of cardiovascular diseases [89] The quinazolone RVX-208, a derivative of the plant polyphenol resveratrol, acts as interaction partner of ApoA1 and performs a preferentially binding ability to the BD2 of BRD3, exhibiting selectivity over BD1 of up to 23-fold [90].